RxDoctor Payments DataLook up a doctor →

Daniel Becker, MD

Neurology · Lutherville, MDNPI 1881741775

Payments from drug & device makers

$4,230,356in general payments, 2019–2025

Across 3,378 payments — averaging $1252.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • AbbVie$800K
  • Sanofi$472K
  • Biogen$353K
  • Genentech, Inc.$242K
  • Roche Products Limited$235K
  • plus $1.1M from 54 others
$3,718in research payments, 2019–2025

Across 23 payments — averaging $161.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$3K
  • AbbVie$1K

What the payments were for

  • Consulting fees$142,3679%
  • Speaking & faculty fees$1,181,29375%
  • Travel & lodging$194,06812%
  • Food & beverage$64,7534%
  • Education$4720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis316$1,022,880
AbbVie(2 entities)288$799,617
Sanofi313$471,598
Biogen184$352,821
Genentech, Inc.31$242,076
Roche Products Limited434$235,189
E.r. Squibb & Sons, L.L.C.175$209,402
Amgen(2 entities)255$200,224
TG Therapeutics, Inc.132$151,230
EMD Serono, Inc.169$135,867
Eisai Inc.164$123,623
Genentech USA, Inc.137$80,170
Vanda Pharmaceuticals Inc.93$73,070
Johnson & Johnson(2 entities)84$47,859
Bristol Myers Squibb218$47,536
Sanofi-aventis U.S. LLC8$13,168
Teva Pharmaceuticals USA, Inc.45$10,985
Sanofi US Services Inc.2$4,800
Lundbeck LLC36$882
Mallinckrodt Hospital Products Inc.14$823
AstraZeneca26$812
Lilly USA, LLC37$736
Mallinckrodt Enterprises LLC7$655
Biohaven Pharmaceuticals, Inc.17$471
Pfizer25$397
Avanir Pharmaceuticals, Inc.19$321
Neurocrine Biosciences, Inc.9$310
Banner Life Sciences, LLC15$300
Kyowa Kirin, Inc.12$249
UCB, Inc.8$237
Biohaven Pharmaceutical Holding Company Ltd.30$208
Upsher-smith Laboratories LLC6$150
CSL Behring5$139
ANI Pharmaceuticals, Inc.5$137
Ipsen Biopharmaceuticals, Inc7$133
Cardinal Health Inc1$132
Argenx US, Inc.4$120
Grifols USA, LLC4$91
Jazz Pharmaceuticals Inc.3$78
GE HealthCare3$75
Axsome Therapeutics, Inc.2$63
Life Molecular Imaging Ltd3$58
Sunovion Pharmaceuticals Inc.3$56
Acorda Therapeutics, Inc3$52
Merz Pharmaceuticals, LLC2$52
Coloplast2$48
Neurelis, Inc.2$44
Arbor Pharmaceuticals, Inc.2$40
Adamas Pharmaceuticals, Inc.2$38
Piramal Critical Care1$36
Microtransponder, Inc.1$32
Astellas Pharma US Inc2$30
Sandoz1$29
Shire North American Group Inc1$27
Springworks Therapeutics, Inc.1$23
Impel Pharmaceuticals Inc.1$20
Tanabe Pharma America, Inc.1$19
Globus Medical1$19
Vertical Pharmaceuticals, LLC1$18
Avion Pharmaceuticals1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,230,356 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$5,913,353
Medicare patients
332
Services billed
129,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide54$628,198
ZeposiaOzanimod Hydrochloride32$369,334
CopaxoneGlatiramer Acetate37$226,569
Teriflunomide65$147,073
AmpyraDalfampridine12$50,262
BotoxOnabotulinumtoxina20$41,298
Dimethyl Fumarate16$38,118
Dalfampridine ErDalfampridine71$24,975
Glatiramer Acetate13$19,762
Aimovig AutoinjectorErenumab-Aooe18$18,554
FingolimodFingolimod Hcl12$6,868
Modafinil27$2,615
Baclofen148$2,304
Armodafinil18$2,134
Solifenacin Succinate11$1,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$471,598$628,19854 claims
E.r. Squibb & Sons, L.L.C.Zeposia$209,402$369,33432 claims
Teva Pharmaceuticals USA, Inc.Copaxone$10,985$226,56937 claims
Acorda Therapeutics, IncAmpyra$52$50,26212 claims
AbbVieBotox$799,617$41,29820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 neurology providers in Maryland.

Other neurology in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →